|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
8229 Boone Blvd, Vienna, Virginia 22182, US
|
|
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.
CEL-SCI's lead investigational therapy, Multikine®* (Leukocyte Interleukin, Injection), is currently being developed as a potential therapeutic agent aimed at harnessing the patient's own immune system to produce an anti-tumor response. Data from Phase I and Phase II clinical trials suggest that Multikine simulates the activities of a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. Multikine is the trademark we have registered for this investigational therapy, and this proprietary name is subject to review by the U.S. Food and Drug Administration, or FDA, in connection with our future anticipated regulatory submission for approval.
|
CEL-SCI Corporation Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
33.33%
|
The widely used CEL-SCI Corporation email format is {f}{last} (e.g. [email protected]) with 33.33% adoption across the company.
To contact CEL-SCI Corporation customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.